-
Mashup Score: 0The top 20 pharma companies by 2023 revenue - 6 day(s) ago
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing sales of its diabetes and obesity treatments Ozempic and Wegovy. Accounting for the changes at the high and low ends of the rankings were plummeting sales of COVID-19 products. | 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
A SHORTAGE of the weight-loss drug Zepbound is driving customers to extremes to secure the coveted treatment — but relief may be right around the corner. Zepbound was released in November as a comp…
Source: www.the-sun.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Mark Cuban's drug company partners with 1st health system - 2 month(s) ago
Community Health Systems partners with Mark Cuban’s pharmaceutical company to address drug supply issues and reduce costs. Two drugs are already in production.
Source: www.beckershospitalreview.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Mark Cuban's pharma company to start manufacturing 2 drugs this week - 2 month(s) ago
“Mark Cuban’s Cost Plus Drug Co. to manufacture epinephrine and norepinephrine at its new Dallas facility, to address drug shortages and lower costs.”
Source: www.beckershospitalreview.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 1Growth of GLP-1s has Implications for Multiple Stakeholders - 2 month(s) ago
Can prescription weight-loss drugs help address a trillion-dollar issue?
Source: www2.deloitte.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 0Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications - 2 month(s) ago
The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Growth of GLP-1s has Implications for Multiple Stakeholders - 2 month(s) ago
Can prescription weight-loss drugs help address a trillion-dollar issue?
Source: www2.deloitte.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 03 issues to watch in pharma in 2024 - 4 month(s) ago
What are the issues to watch in pharma in 2024? The past is likely prologue.
Source: www.statnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3How Might IRA’s Drug-Pricing Provisions Affect Stakeholders - 4 month(s) ago
As drugs become subject to price negotiation, how will pharma companies and other stakeholders be affected?
Source: www2.deloitte.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 05 years in, Civica Rx makes 80 drugs for 1/3 of US hospitals - 6 month(s) ago
Civica Rx, a hospital-owned pharmaceutical company, has been working to reduce drug shortages since 2018. They now work with hundreds of hospitals and make 80 drugs currently in shortage.
Source: www.beckershospitalreview.comCategories: General Medicine News, General HCPsTweet
The top 20 #pharma companies by 2023 revenue https://t.co/FmKzmv2T2m